Comirnaty |
mRNA |
above 12 years old |
2 doses (second 3 weeks after first); booster dose 6 months after second |
local side effects, flulike symptoms, myocarditis, pericarditis, erythema multiforme |
91.3–95.0% |
Spikevax |
mRNA |
above 12 years old old |
2 doses (second 28 days after first); booster dose 6 months after second |
local side effects, flulike symptoms, myocarditis, pericarditis, erythema multiforme |
94.1% |
COVID-19 Vaccine Janssen |
vector (adenoviral) |
above 18 years old old |
1 dose, booster dose after 2 months |
local side effects, flulike symptoms, thrombosis, thrombocytopenia, VITT, CLS, Guillain-Barre syndrome |
66.1–85.4% |
Vaxzevria |
vector (adenoviral) |
above 18 years old |
2 doses, the second 4 to 12 weeks after the first |
local side effects, flulike symptoms, thrombosis, thrombocytopenia, VITT, CLS, Guillain-Barre syndrome |
59.5–74.0% |
Nuvaxovid |
Protein subunit vaccine |
above 18 years old |
2 doses, the second after 3 weeks. |
local side effects, flulike symptoms |
89.7% |